Clinical trials: Severe Psoriasis
Moderate to Severe Plaque-type Psoriasis
Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
This study is designed to support the optimal use of secukinumab by providing data to refine guidance on dosing flexibility in patients with psoriasis.
- Trial name
- GAIN (NCT02474069)
- Testing
- Secukinumab
- Where
- 89 sites in Germany
- Volunteers
- 772 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)
This was a multicenter, prospective, 5-year surveillance study of approximately 5000 Raptiva-treated patients and approximately 500 non-Raptiva treated patients (formerly 2500 comparison patients who were treated with a biologic…
- Trial name
- RESPONSE (NCT00096928)
- Where
- 182 sites in United States
- Volunteers
- 1,846 people
- Sponsor
- Genentech, Inc.
Moderate to Severe Chronic Plaque Psoriasis
A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China
This was a non-interventional, prospective, multi-center real world setting study, aiming to provide safety and effectiveness data in Chinese pediatric patients with moderate to severe plaque psoriasis treated with Cosentyx® for…
- Trial name
- NCT05388916
- Testing
- Cosentyx
- Where
- 7 sites in China
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Clinical Study of Stage IV Psoriasis in Children With Geleli
This study is a multicenter, prospective, observational phase IV clinical study. A total of 80 children and adolescents with severe plaque psoriasis were included in the study.
- Trial name
- NCT05803187
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Bio-Thera Solutions
Psoriasis
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
- Trial name
- NCT03240809
- Testing
- Brodalumab
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g
This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who previously participated in…
- Trial name
- NCT00096603
- Testing
- Raptiva (efalizumab)
- Volunteers
- 450 people
- Sponsor
- Genentech, Inc.
Psoriasis, Metabolic Syndrome
Peds Metabolic Syndrome in Psoriasis
The objective of this study is to assess whether there is an increased risk of the metabolic syndrome in children with psoriasis compared to children without psoriasis.
- Trial name
- NCT00930592
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Tufts Medical Center
Moderate to Severe Chronic Plaque-type Psoriasis
Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT03668613
- Testing
- secukinumab low dose, secukinumab high dose
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis Vulgaris
Pre-Post Multimodal Assessment Of Severe Psoriasis Vulgaris Using Clinical, Dermoscopic And QoL Measures
The goal of this observational study is to learn about the comprehensive changes in severe plaque psoriasis (Psoriasis Vulgaris) in adult participants undergoing standard treatment.
- Trial name
- NCT07495657
- Volunteers
- 45 people
- Sponsor
- Assiut University
Plaque Psoriasis
Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis
The aim of the study is to evaluate the efficacy and safety of netakimab compared with placebo in a pediatric population of subjects over 6 years of age with moderate to severe plaque psoriasis.
- Trial name
- PLANETA-KIDS (NCT06640517)
- Testing
- Netakimab, Adalimumab
- Where
- 14 sites in Russia
- Volunteers
- 140 people
- Sponsor
- Biocad
Post-Acute COVID-19 Syndrome, ME/CFS
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related…
- Conditions
- Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA)
- Trial name
- NCT04806620
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Brain Inflammation Collaborative
Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis
A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis
The purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of…
- Conditions
- Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis
- Trial name
- CIMcare (NCT04123795)
- Testing
- Certolizumab pegol
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 49 people
- Sponsor
- UCB Biopharma SRL
Plaque Psoriasis
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in children and adolescent participants aged 4 to <18 years with moderate to severe plaque psoriasis.
- Trial name
- NCT04772079
- Testing
- Deucravacitinib
- Where
- 65 sites in Argentina, Australia and 11 more
- Volunteers
- 153 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
Micellar Paclitaxel to Treat Severe Psoriasis
This study will evaluate the safety and effectiveness of micellar paclitaxel for treating severe psoriasis. Paclitaxel in another formulation (Taxol) is approved by the Food and Drug Administration for use in patients with…
- Trial name
- NCT00006276
- Testing
- Micellar Paclitaxel
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Psoriasis
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT03701763
- Testing
- Apremilast (CC-10004)
- Where
- 99 sites in United States, Belgium and 8 more
- Volunteers
- 245 people
- Sponsor
- Amgen
Psoriasis
Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis
To establish the safety of alefacept when administered to adolescent subjects with moderate to severe psoriasis.
- Trial name
- NCT00808223
- Testing
- alefacept
- Where
- 5 sites in United States, Bulgaria and 1 more
- Volunteers
- 30 people
- Sponsor
- Astellas Pharma Inc
Rheumatoid Arthritis, Crohn's Disease
The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists
The RATIO registry is a French registry designed by a multidisciplinary group to collect data on opportunistic and severe bacterial infections and lymphoma in patients treated with TNF-a antagonists ( infliximab, etanercept and…
- Conditions
- Rheumatoid Arthritis, Crohn's Disease, Ankylosing Spondylitis, Psoriasis
- Trial name
- NCT00224562
- Testing
- TNF-alpha antagonists
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Psoriasis
Oral Chinese Herbal Medicine Concurrent With Secukinumab for Severe Plaque Psoriasis
The aim of this study is to determine whether oral Chinese herbal medicine in combination secukinumab is effective and safe in the treatment of severe psoriasis.
- Trial name
- NCT04414605
- Testing
- Gu Ben Hua Yu Fang decoction (Chinese herbal medicine), Secukinumab Auto-Injector [Cosentyx]
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
Rheumatoid Arthritis (RA), Atopic Dermatitis (AD)
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints characterized by the swelling of multiple joints and tenderness caused by progressive inflammatory synovitis, which leads to serious and debilitating diseases.
- Conditions
- Rheumatoid Arthritis (RA), Atopic Dermatitis (AD), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
- Trial name
- NCT04541810
- Where
- 116 sites in South Korea
- Volunteers
- 2,369 people
- Sponsor
- AbbVie
Moderate-to-severe Chronic Plaque Psoriasis
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
The study has been designed with three components. Part A is an open label PK study followed by a randomized trial component (Part B) followed by open label Long Term Extension (LTE).
- Trial name
- NCT03997786
- Testing
- Tildrakizumab, Etanercept
- Where
- 27 sites in United States, Hungary and 4 more
- Volunteers
- 135 people
- Sponsor
- Sun Pharmaceutical Industries Limited